Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Review

Therapeutic Targeting of Mitochondrial One-Carbon Metabolism in Cancer

Aamod S. Dekhne, Zhanjun Hou, Aleem Gangjee and Larry H. Matherly
Aamod S. Dekhne
1Department of Oncology, Wayne State University School of Medicine, and the Barbara Ann Karmanos Cancer Institute, Detroit, Michigan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Aamod S. Dekhne
Zhanjun Hou
1Department of Oncology, Wayne State University School of Medicine, and the Barbara Ann Karmanos Cancer Institute, Detroit, Michigan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Zhanjun Hou
Aleem Gangjee
2Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Larry H. Matherly
1Department of Oncology, Wayne State University School of Medicine, and the Barbara Ann Karmanos Cancer Institute, Detroit, Michigan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: matherly@karmanos.org
DOI: 10.1158/1535-7163.MCT-20-0423 Published November 2020
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

One-carbon (1C) metabolism encompasses folate-mediated 1C transfer reactions and related processes, including nucleotide and amino acid biosynthesis, antioxidant regeneration, and epigenetic regulation. 1C pathways are compartmentalized in the cytosol, mitochondria, and nucleus. 1C metabolism in the cytosol has been an important therapeutic target for cancer since the inception of modern chemotherapy, and “antifolates” targeting cytosolic 1C pathways continue to be a mainstay of the chemotherapy armamentarium for cancer. Recent insights into the complexities of 1C metabolism in cancer cells, including the critical role of the mitochondrial 1C pathway as a source of 1C units, glycine, reducing equivalents, and ATP, have spurred the discovery of novel compounds that target these reactions, with particular focus on 5,10-methylene tetrahydrofolate dehydrogenase 2 and serine hydroxymethyltransferase 2. In this review, we discuss key aspects of 1C metabolism, with emphasis on the importance of mitochondrial 1C metabolism to metabolic homeostasis, its relationship with the oncogenic phenotype, and its therapeutic potential for cancer.

Introduction

Metabolic reprogramming is a hallmark of cancer (1). Of the altered metabolisms in cancer, one-carbon (1C) metabolism is especially noteworthy. While 1C metabolism in the cytosol has been an important therapeutic target for cancer since the inception of modern chemotherapy (typified by aminopterin, methotrexate, and 5-fluorouracil; refs. 2, 3), increasing attention has been focused on mitochondrial 1C metabolism and its importance to the malignant phenotype as a critical source of 1C units, glycine, reducing equivalents, and ATP (4–8). Indeed, growing evidence suggests that serine hydroxymethyltransferase 2 (SHMT2) and 5,10-methylene tetrahydrofolate dehydrogenase 2 (MTHFD2), the first and second enzymes in the serine catabolic pathway in mitochondria, are independent prognostic factors and potential therapeutic targets for a number of cancers (9–14). In this review, we discuss key aspects of 1C metabolism with particular emphasis on the importance of mitochondrial 1C metabolism to metabolic homeostasis, its relationship with the oncogenic phenotype, and its therapeutic potential for cancer.

Folate Homeostasis and Compartmentation of Cellular 1C Metabolism

Folates encompass a group of water soluble compounds within the vitamin B9 family composed of pteridine, p-aminobenzoic acid, and L-glutamate moieties (15). While many species from bacteria to plants synthesize folates de novo, mammals cannot (4, 16). Accordingly, folate cofactors must be acquired through the diet (e.g., leafy green vegetables) as reduced forms or as folic acid in fortified foods.

Reflecting their hydrophilic nature, circulating folates have limited capacities to diffuse across plasma membranes. Accordingly, mammalian cells have evolved sophisticated uptake systems (Fig. 1) to facilitate folate transport across plasma membranes, most notably the reduced folate carrier (RFC; SLC19A1; refs. 17–19) and the proton-coupled folate transporter (PCFT; SLC46A1; refs. 18, 19). The ubiquitously expressed RFC is the major uptake mechanism for folates into tissues and tumors from the systemic circulation (17–19). RFC is a folate–anion antiporter and exchanges reduced folates for organic anions such as organic phosphates (17–19). PCFT is a proton–folate symporter that facilitates absorption of dietary folates at the acidic pH (∼ pH 6) of the upper gastrointestinal (GI) tract (19). While PCFT is also detected in the kidney, liver, placenta, and spleen (20, 21), it is not a major folate transporter in most normal tissues as its activity is very low in tissues outside the upper GI tract secondary to bicarbonate inhibition (at neutral pH; ref. 22). PCFT is optimally active at acidic pH (pH 5–5.5), with detectable activity up to pH 6.5–7 (23). PCFT is expressed in tumors including non–small cell lung cancer (24), malignant pleural mesothelioma (25), epithelial ovarian cancer (26), and pancreatic cancer (27), where it functions in the cellular uptake of folates and related compounds at the acidic pH characterizing the microenvironments of many tumors (20, 23).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

1C metabolism reactions, intermediates, and products. 1C metabolism is compartmentalized into the mitochondria and cytosol with a smaller pool in the nucleus. Folates are transported across the plasma membrane by the RFC (SLC19A1) and PCFT (SLC46A1). Serine is generated from glycolysis intermediates. Serine then enters the mitochondria and provides 1C units for the serine cycle (noted with bold blue arrows). Formate is exported to the cytosol where it serves as a source of 1C units for biosynthetic reactions. Nuclear 1C metabolism generates dTMP from dUMP to eliminate uracil misincorporation in DNA. Nuclear enzymes, in light blue, undergo SUMOylation in the cytosol and are imported into the nucleus during S-phase. Folate uptake into the mitochondria is mediated by the MFT (SLC25A32). 2-PG, 2-phosphoglycerate; FAICAR, 5-formamidoimidazole-4-carboxamide ribonucleotide; FGAR, formyl glycinamide ribonucleotide; f-Met, formyl methionine; GAR, glycinamide ribonucleotide; MTFMT, methionyl tRNA formyl transferase; PEP, phosphoenolpyruvate; THF, tetrahydrofolate.

Following internalization, folates are compartmentalized in the cytosol and the mitochondria (28), with a smaller pool in the nucleus (Fig. 1; ref. 29). In the cytosol, folate cofactors participate in 1C-dependent metabolism, leading to the synthesis of thymidylate, purine nucleotides, serine, and methionine (15). Cytosolic and mitochondrial 1C pathways are interconnected by an interchange between serine, glycine, and formate (Fig. 1; refs. 4, 5, 28), with uptake of folates from the cytosol into mitochondria via a “mitochondrial folate transporter” (MFT; SLC25A32; refs. 30, 31). MFT is the only known transporter of folates from the cytosol into the mitochondrial matrix (31) and is a member of the mitochondrial carrier family, which includes the ATP/ADP exchange carrier and the phosphate carrier (32).

In the cytosol and mitochondria, folates are substrates for alternate isoforms of folylpoly-γ-glutamate synthetase (FPGS), representing splice variants encoded by a single gene (33). FPGS catalyzes the conjugation of up to eight additional glutamate residues to the γ-carboxyl of the terminal glutamate of folate substrates (34). Polyglutamyl folates are the preferred substrates for C1 transfer reactions (34). Furthermore, cytosolic folate polyglutamates are retained in cells (34), and mitochondrial folate polyglutamates do not exchange with cytosolic forms (33).

In mitochondria, folates are required for 1C metabolism originating from serine (Fig. 1). Serine catabolism involves three primary steps, catalyzed by SHMT2, MTHFD2 (or methylene tetrahydrofolate dehydrogenase 2-like, MTHFD2L), and methylene tetrahydrofolate dehydrogenase 1-like (MTHFD1L; ref. 4). The net result is generation of glycine and 1C units, with MTHFD1L catalysis resulting in conversion of 10-formyl tetrahydrofolate (10-CHO-THF) to formate, which passes to the cytosol. Serine catabolism in mitochondria serves as the principal source of 1C units and glycine for cellular biosynthesis, including de novo synthesis of purine nucleotides and thymidylate in the cytosol (4–7). Cells deficient in mitochondrial 1C metabolism or MFT are glycine auxotrophs and can require exogenous formate for survival (31, 35, 36). Mitochondrial 1C metabolism is also an important source of NAD(P)H and glycine for glutathione (GSH) synthesis and ATP (refs. 4, 6, 7, 37; see below).

In the cytosol, 10-CHO-THF is resynthesized from formate and tetrahydrofolate by MTHFD1 (Fig. 1), a trifunctional enzyme that includes dehydrogenase, cyclohydrolase, and 10-formyl tetrahydrofolate synthetase activities (38). This provides 10-CHO-THF substrate for de novo purine biosynthesis [by glycinamide ribonucleotide formyl transferase (GARFTase) and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) formyltransferase (AICARFTase)] and 5,10-methylene tetrahydrofolate (5,10-CH2-THF) for thymidylate synthase (TS) and other reactions including SHMT1 (Fig. 1). De novo purine biosynthesis includes 10 sequential reactions from phosphoribosyl pyrophosphate (PRPP) to IMP (Fig. 1; ref. 39). To facilitate an efficient flux of pathway intermediates, these enzymes assemble into a structure termed the “purinosome” (39), which sequesters pathway intermediates and reduced folates, and colocalizes with mitochondria to consume five moles of ATP per mole of IMP synthesized. SHMT1 converts glycine to serine with 1C units from 5,10-CH2-THF (Fig. 1). Thymidylate is synthesized from dUMP and 5,10-CH2-THF by TS, generating dihydrofolate (DHF) which, in turn, is reduced to the active tetrahydrofolate form by dihydrofolate reductase (DHFR; ref. 15). Interestingly, TS and DHFR (as DHFR-like 1 or DHFRL1) are also expressed in mitochondria to protect the integrity of mitochondrial DNA (40). While the impact of noncytosolic thymidylate biosynthesis on therapeutic targeting with antifolate drugs (below) is not entirely clear, evidence suggests a role in response to TS inhibitors (41).

5,10-CH2-THF is metabolized in the cytosol to 5-methyl tetrahydrofolate by 5,10-methylene tetrahydrofolate reductase (MTHFR; Fig. 1; ref. 42). 5-Methyl tetrahydrofolate is a methyl donor in the conversion of homocysteine to methionine by the vitamin B12–dependent enzyme, methionine synthase (MTR; ref. 43). Furthermore, methionine is converted by methionine adenosyltransferase (S-adenosyl methionine synthetase, SAMS) into S-adenosyl methionine (SAM), which is required for methylation of DNA, phospholipids, and proteins (44). Thus, serine metabolism in the mitochondria supports cellular methylation reactions via 5-methyl tetrahydrofolate–dependent methylation of homocysteine and de novo synthesis of ATP.

The 1C reactions depicted in Fig. 1 (beginning with serine in mitochondria) can be viewed as proceeding in a clockwise direction. This reflects the high NAD(P)+/NAD(P)H ratios in mitochondria that favor serine oxidation to formate, and low NADP+/NADPH ratios in the cytosol that favor conversion of formate to 10-CHO-THF by MTHFD1 and eventually to serine (via SHMT1; ref. 28). When the mitochondrial 1C pathway is lost (e.g., deletion of SHMT2 or MTHFD2), rapid depletion of cytosolic 10-CHO-THF reverses the thermodynamic favorability of the MTHFD1 reaction, resulting in a compensatory reversal of the cytosolic 1C flux (serine → formate) to meet cellular 1C demand (45). However, this compensation is incomplete as these cells exhibit signs of 1C stress (reflected in increased cellular AICAR) and glycine auxotrophy (4, 35, 45). Interestingly, whereas SHMT1 and MTHFD1 reversal compensates for the loss of the mitochondrial 1C pathway, SHMT1 regulates translation of SHMT2 via direct binding to SHMT2 mRNAs when cellular glycine and folate levels are high (46).

In addition to SHMT1 and SHMT2, an alternatively transcribed SHMT2 isoform (SHMT2α), lacking a mitochondrial targeting sequence (47), is transcribed from a distinct gene (48) and is at least partly localized to the nucleus along with TS, DHFR, SHMT1, and MTHFD1 (29). These proteins undergo posttranslational modifications involving the small ubiquitin-like modifier (SUMO) and are translocated from the cytosol to the nucleus at the onset of S-phase where they associate with the DNA repair/replication machinery (“replitase;” ref. 49) to generate nuclear thymidylate, which limits uracil misincorporation into DNA (29) during repair and replication. MTHFD2 was reported (50) to promote tumor cell proliferation by localizing to the nucleus, suggesting a noncanonical role in tumor progression. MTHFD2 has also been reported to interact with RNA processing proteins to regulate DNA repair and regulation (51) and to play a role in controlling global N6-methyladenosine methylation, including hypoxia-inducible factor (HIF) 2α mRNA (52).

Serine Biosynthesis, Mitochondrial 1C Metabolism, and Cancer

Synthesis of serine is upregulated in cancer (53, 54). Serine is synthesized from 3-phosphoglycerate (3-PG) with 3-phosphoglycerate dehydrogenase (PGDH) as the first committed step (Fig. 1; ref. 54). PGDH is overexpressed in breast cancers and melanomas, in part, due to gene amplification (53, 55). The 3-phosphopyruvate product is transaminated by phosphoserine aminotransferase 1 (PSAT1) into 3-phosphoserine (3PS), which is converted into serine by phosphoserine phosphatase (PSPH; ref. 54). Serine is an allosteric inhibitor of PGDH (56) and regulates its own synthesis. Furthermore, serine is a ligand and allosteric activator of pyruvate kinase M2 (PKM2), which is expressed in proliferating cancer cells. Thus, under conditions of serine deprivation, PKM2 activity is reduced and more glucose-derived carbon is channeled into serine biosynthesis to support cell proliferation (57). Serine is actively transported from the cytosol into mitochondria by sideroflexin 1/3 (SFXN1/SFXN3; Fig. 1; ref. 58).

Serine catabolism is often activated in cancer, with the genes encoding SHMT2 and MTHFD2 among the most overexpressed metabolic genes in all human cancers as compared with normal tissues (59). Metabolomics analyses of 219 extracellular metabolites from the NCI-60 cancer cell lines showed that glycine consumption and serine catabolism including SHMT2, MTHFD2, and MTHFD1L closely correlated with cancer cell proliferation (60). High levels of expression of these enzymes in cancer cells may, in part, reflect their regulation by MYC as MYC binds to the promoters for SHMT2 and MTHFD2, as well as for MTHFD1L (61, 62). MTHFD2 is a tumor-selective target which is not significantly expressed in differentiated adult cells (63). Thus, targeting mitochondrial 1C metabolism at a number of levels would likely afford selective tumor inhibition, sparing normal tissues.

In MDA-MB-231 breast cancer cells and tissue-tropic metastatic subclones, serine catabolic enzymes in mitochondria are further upregulated, suggesting their critical roles as drivers of proliferation of a subset of metastatic breast cancers (64). Overexpression of SHMT2 and/or MTHFD2 has been associated with poor prognosis for a number of cancers including breast cancer (12, 59, 64, 65), non–small cell lung cancer (66), pancreatic cancer (11), gliomas (67), cholangiocarcinoma (10), and GI cancers (including esophageal, gastric, and colon cancers; ref. 9). SHMT2 expression is also increased in invasive breast cancer, adrenocortical carcinoma, chromophobe renal cell carcinoma, and papillary renal cell carcinoma, including late-stage tumors (64). This suggests that targeting SHMT2 and/or MTHFD2 could be promising for treating late-stage tumors.

Serine catabolism in mitochondria serves as the principal source of 1C units for cellular biosynthesis, including de novo synthesis of purine nucleotides and thymidylate in the cytosol, and SHMT2 provides >85% of glycine for proteins, purines, and GSH in tumor cells (4–8). Mitochondrial 1C metabolism is a major source of NAD(P)H for synthesis of macromolecules and protection against oxidative stress (6, 37, 68). In mitochondria, glycine is required for heme biosynthesis (69).

SHMT2 catalyzes the conversion of serine to glycine with the generation of 5,10-CH2-THF (Fig. 1). SHMT2 is essential for cell survival under hypoxic (6) or ischemic (14) conditions and is upregulated by HIF1α in a MYC-dependent manner (6). As MYC-transformed cells rely on SHMT2 to sustain 1C and glycine pools, and on NAD(P)H for cell survival under hypoxic conditions (6), therapeutic targeting of SHMT2 (below) should be selective against hypoxic MYC-transformed tumors that are resistant to other modalities such as radiation. Knockout of SHMT2 (in HCT116 and Jurkat cells) was accompanied by increased glycolytic flux, suggesting defects in oxidative phosphorylation (70, 71). SHMT2 knockout impairs formylation of the initiating methionine tRNA (formyl-Met-tRNA), resulting in decreased translation of mitochondria-encoded complex I and IV subunits, leading to reduced basal and maximal respiratory capacities (71). 5,10-CH2-THF is also important for synthesis of the taurinomethyluridine base of other tRNAs (e.g., lysine and leucine) in mitochondria (70).

SHMT2 is a substrate of histone deacetylase (HDAC) enzymes, which modulates enzyme activity. Desuccinylation of SHMT2 by SIRT5, a class III HDAC and member of the sirtuin family (72), promotes carcinogenesis through activation of SHMT2 catalytic activity (73). While the enzymatically active SHMT2 tetramer is stabilized by pyridoxal phosphate (74), the inactive dimer binds the deubiquitinating BRCC36 isopeptidase complex (BRISC), preventing degradation of plasma membrane type I IFN receptors and promoting inflammatory signaling (75). HDAC11 deacylates SHMT2 and prevents its association with BRISC; this permits ubiquitination and sequestration of type I IFN receptors (76). As HDAC11 is overexpressed in multiple cancers, HDAC11-mediated SHMT2 deacylation could enable broad spectrum suppression of immune response by cancer cells (77).

MTHFD2 is a bifunctional enzyme with dehydrogenase and cyclohydrolase activities that converts 5,10-CH2-THF to 10-CHO-THF with synthesis of NADH from NAD+ (Fig. 1; ref. 78). MTHFD2 can also use NADP+ as a cofactor to generate mitochondrial NADPH (63). MTHFD2 was originally reported to be expressed in transformed, embryonic, and undifferentiated adult cells, whereas MTHFD2L is expressed in differentiated adult cells and at all stages of embryogenesis (79). While recent studies found that normal and cancer cells express both enzymes, MTHFD2L is unlikely to have an important role in cancer (80). For MTHFD2, regulation by MYC and mTOR (81, 82) is consistent with its essential role in supporting the increased biosynthetic demands of rapidly proliferating cells (78). In lung cancer, MTHFD2 was implicated in gefitinib resistance and cancer stem–like properties by depleting cellular AICAR (83).

Downstream from MTHFD2 is the enzyme MTHFD1L (Fig. 1; ref. 78), which catalyzes the reverse 10-formyl tetrahydrofolate synthetase reaction by which 10-CHO-THF is converted to tetrahydrofolate, formate, and ATP. Generation of ATP in this step is significant such that when combined with that from NADH and oxidative phosphorylation, each formate generated from serine yields 3.5 ATPs (84). In proliferating cancer cells, synthesis of 1C units exceeds the 1C demand for purine biosynthesis (84). Indeed, formate “overflow” is a characteristic of oxidative cancers and is associated with tumor invasion (85). Formate generated in the mitochondria and exported to the cytosol serves an important “protective” role in limiting loss of unsubstituted tetrahydrofolate by oxidative stress (86).

Glycine is the product of SHMT2 catalysis and itself can be a source of 1C units via the mitochondrial glycine cleavage system (GCS; ref. 87). The GCS including glycine decarboxylase (GDC) converts glycine to CO2, NH3, and 5,10-CH2-THF (Fig. 1). While the importance of the GCS as a source of reducing potential is uncertain, overexpression of GDC was reported to drive tumor formation in lung adenocarcinomas (88). Furthermore, in gliomas with high levels of SHMT2, the GCS is important for clearing glycine because loss of activity results in accumulation of the toxic glycine metabolites, aminoacetone and methylglyoxal (14). Increased glycine can also impair cell growth and decrease NAD(P)H and 5,10-CH2-THF, possibly due to a reversal of SHMT2 catalysis (89).

Mitochondrial NADPH can also be generated by the catabolism of 10-CHO-THF to CO2 and tetrahydrofolate by aldehyde dehydrogenase 1 family member L2 (ALDH1L2; Fig. 1; ref. 90). ALDH1L2 is approximately 72% homologous to its cytosolic counterpart, aldehyde dehydrogenase 1 family member L1 (ALDH1L1). Although ALDH1L1 is involved in regulating cell proliferation through its control of tetrahydrofolate pools, ALDH1L2 is a major source of NADPH in mitochondria (68, 90).

Serine is converted to glycine via SHMT2 and is a precursor of cysteine (via the transsulfuration pathway), both of which are important for synthesis of GSH (7). MTHFD2 with ALDH1L2 (Fig. 1) provide reducing equivalents (such as NADH and NADPH), which are essential for redox homeostasis and resistance to oxidative stress (63, 68). Knockdown of SHMT2, MTHFD2, or ALDH1L2 increased reactive oxygen species, with concomitant decrease in cellular ratios of NAD(P)H to NAD(P)+ and reduced to oxidized GSH (68). This increased redox stress results in increased cell death that could be rescued by N-acetylcysteine (6). ALDH1L2 levels are elevated in many tumor types (90) and ALDH1L2 was implicated in metastasis in a mouse melanoma model, associated with its role in counteracting oxidative stress (91). Thus, mitochondrial 1C metabolism is important for redox homeostasis and oxidative stress. Furthermore, NRF2, a key regulator of antioxidant response (37, 92–94), regulates expression of genes involved in serine synthesis (PDGH and PSAT1) and catabolism (SHMT2) via ATF4 (66, 95). This, in turn, regulates cellular responses to amino acid starvation.

p53 is associated with the capacity of cancer cells to adapt to serine starvation and oxidative stress, and, indeed, p53 is activated upon serine deficiency, resulting in p21 cell-cycle arrest (96). This diverts metabolism toward GSH synthesis to combat oxidative stress. The protective effects of p53 under serine-depleted conditions suggest that p53-null tumors could be particularly vulnerable to serine depletion (96).

The unique demands of tumor cells for 1C units and glycine, and for redox balance under hypoxia (4–6, 8), combined with the high levels of expression of serine biosynthetic and catabolic pathways in cancers versus normal tissues (53, 54, 59, 60), suggest that SHMT2 and MTHFD2 could be important therapeutic targets for cancer. Thus, targeting mitochondrial 1C metabolism would likely afford selective tumor inhibition, sparing normal tissues. In the following sections, we describe progress toward developing therapeutics for direct targeting of SHMT2 and MTHFD2 in cancer.

Discovery of MTHFD2 Inhibitors for Cancer

In acute myeloid leukemia (AML), downregulation of MTHFD2 is commonly associated with several treatments that cause AML-related death and differentiation (i.e., 1,25-dihydroxy vitamin D3, PMA, all trans retinoic acid, JQ1, and EPZ004777; ref. 81). This is particularly pronounced in FLT3-ITD AMLs with poor prognoses to standard therapies (61). In breast cancer, MTHFD2 overexpression correlated with metastasis and invasion (97), and with poor prognosis (13). Knockdown of MTHFD2 in breast cancer cells (98) increased the dependence on extracellular glycine that could not be rescued by formate supplementation. Metabolomics analyses in these MTHFD2-knockdown cells revealed decreased mitochondrial 1C metabolism, coupled with increased glycolytic and glutaminolytic fluxes (98).

MTHFD2 has 40% sequence identity with MTHFD1, the cytosolic isoform (78). Although early crystallization of MTHFD1 in complex with inhibitors (99) identified critical catalytic residues, such as Lys56, Ser49, and Cys147, the development of small-molecule inhibitors of MTHFD2 has remained challenging. Initial efforts to identify MTHFD2 inhibitors focused on the antibacterial benefits from inhibiting the bacterial MTHFD2 ortholog, FolD (100). A high-throughput screening assay to identify inhibitors of FolD in Pseudomonas aeruginosa identified several compound leads; however, these showed modest enzyme inhibition and could not provide scaffolds for further development as MTHFD2 inhibitors. The macrolide keto-carboxylic acid, carolacton (Fig. 2), produced by the myxobacterium Sorangium cellulosum inhibited FolD, as well as MTHFD2, in the low nanomolar range (101). However, carolacton was a poor inhibitor of tumor cell proliferation, as the EC50 values against human cancer cell lines (i.e., HCT116, KB, and U937) in vitro were in excess of 10 μmol/L, with drug export cited as the main hurdle (101).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

MTHFD2 inhibitors. MTHFD2 inhibitors include the macrolide keto-carboxylic acid, carolacton, produced by the myxobacterium Sorangium cellulosum (101) and the Eli Lilly compound LY345899 (102). Newer agents include the Daiichi Sankyo compounds DS44960156 (104) and DS18561882 (105).

Studies with LY345899 (Eli Lilly; Fig. 2) yielded the first crystal structure of an inhibitor complexed with MTHFD2, NAD+, and inorganic phosphate (102). While LY345899 inhibited human MTHFD2 (IC50 = 663 nmol/L), it was a more potent inhibitor of MTHFD1 (IC50 = 96 nmol/L; ref. 102); however, there was no loss of viability for tumor cells (U2OS and Hs-587T) treated with LY345899 in vitro (102). Although LY345899 was reported to suppress growth of a SW620 colorectal cancer xenograft and a colorectal cancer patient-derived xenograft (PDX) in vivo (103), it is unclear whether this response was due to inhibition of MTHFD1 or MTHFD2.

A novel isozyme-selective MTHFD2 inhibitor, DS44960156 (Fig. 2), with a tricyclic coumarin scaffold, was initially discovered via high-throughput screening, and then modified by structure-based drug design (104). DS44960156 was >18-fold more selective toward human MTHFD2 (IC50 = 1.6 μmol/L) than MTHFD1 (IC50 > 30 μmol/L; ref. 104). Further optimization of this scaffold yielded DS18561882 (Fig. 2), with potent inhibition of MTHFD2 (IC50 = 6.3 nmol/L) and 90-fold selectivity for MTHFD2 over MTHFD1 (105). When administered orally, DS18561882 demonstrated remarkable in vivo efficacy against triple-negative breast cancer MDA-MB-231 xenografts in nude mice with minimal treatment-related toxicity (105). DS18561882 would seem to be a promising candidate for future clinical evaluation.

Discovery of SHMT2-targeted Therapeutics for Cancer

SHMT2 is 60% homologous to SHMT1 (35), suggesting that inhibitors of SHMT2 would likely target both enzymes. Knockdown of SHMT1 in HCT116 colon cancer xenografts in immunocompromised mice had no impact on tumor proliferation, whereas SHMT2 knockdown slightly suppressed cell proliferation (36). Knockdown of both SHMT1 and SHMT2 exerted profound inhibition of tumor progression (36), suggesting that dual inhibition of both SHMT1 and SHMT2 is essential (45).

Classic antifolates, including lometrexol, pemetrexed, and methotrexate, were tested as inhibitors of SHMT1 in vitro (106, 107), all with modest activity. Lometrexol showed a Ki of 20 μmol/L (106); the Ki for pemetrexed was 19.1 μmol/L (107), approximately 500-fold less potent than that for TS (109 nmol/L; ref. 108). Toward human SHMT2, an IC50 value of approximately 100 μmol/L was reported for lometrexol (109). Analogous results were reported for pemetrexed with SHMT2 (35). While inhibitions may be greater for polyglutamyl drug forms, these results, nonetheless, suggest that any biological effects of classic antifolates resulting from direct targeting of SHMT1 and SHMT2 are likely to be minor.

Early efforts to generate targeted small inhibitors of SHMT proteins initially focused on herbicidal pyrazolopyran compounds originally described as inhibitors of plant SHMT (Fig. 3A; ref. 110). Optimization of these compounds (Fig. 3B) yielded molecules with antimalarial activity (111). Although these were inhibitors of Plasmodium falciparum and P. vivax SHMTs in vitro (submicromolar IC50s), they were poorly active against rat L6 myeloblasts or HepG2 human hepatoma cells (111). Additional pyrazolopyran compounds were tested against A549 and H1299 human lung cancer cells (112) and a lead compound (compound 2.12) was reported to preferentially inhibit SHMT1 over SHMT2 and effect apoptosis with an LD50 of 34 μmol/L.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

SHMT2 inhibitors. A, SHMT2 inhibitors include the early-generation pyrazolopyran compounds originally designed as inhibitors of plant SHMT2 (110).The pyrazolopyran scaffold was later optimized for inhibition of Plasmodium SHMT (ref. 111; B) and human SHMT1/2, with RZ-2994 or SHIN1 (ref. 36; C) and SHIN2 (ref. 114; D).

The pyrazolopyran series was further optimized by Rabinowitz and colleagues for inhibition against human SHMT1 and SHMT2. The first study using these optimized compounds (113) showed potent (nanomolar) inhibition of isolated human SHMT1 and SHMT2. The IC50 value for the lead compound RZ-2994 (later renamed SHIN1 for “SHMT inhibitor 1”; Fig. 3C) toward human T effector cells was in the low micromolar range, suggesting its therapeutic potential. Although not an analog of folic acid, a crystal structure of SHIN1 in complex with SHMT2 (36) revealed its binding at the folate binding site of SHMT2.

Ducker and colleagues further assessed these optimized pyrazolopyran SHMT inhibitors against human tumor cell lines (36). Against wild-type HCT116 colon cancer cells in vitro, SHIN1 inhibited proliferation with a submicromolar potency (IC50 = 870 nmol/L), with complete pharmacologic rescue by formate and glycine, suggesting on-target inhibition of SHMT2 (36). The IC50 value for SHIN1 in SHMT2-knockout HCT116 cells decreased nearly two orders of magnitude to approximately 10 nmol/L, reflecting potent inhibition of SHMT1 in addition to SHMT2, whereas the IC50 value in SHMT1-knockout cells was indistinguishable from that in wild-type cells (36). This confirmed that efficacy toward wild-type HCT116 cells was primarily due to its inhibition of SHMT2 rather than SHMT1. However, inhibition of both enzymes is essential, as this prevents metabolic compensation by reversal of SHMT1 catalysis (serine → glycine) and synthesis of glycine in response to loss of SHMT2 (45).

Interestingly, enhanced potency of SHIN1 toward 8988T pancreatic cancer cells and diffuse large B-cell lymphoma cells revealed distinct metabolic vulnerabilities of these cancer types that could be exploited by SHMT1 and SHMT2 inhibition (36). 8988T cells exhibit defects in mitochondrial 1C metabolism with an overreliance on SHMT1, whereas B-cell lymphomas have intrinsic defects in glycine uptake that render these cells overly reliant on glycine synthesis from serine by SHMT2 (36). Addition of formate did not rescue B-cell lymphomas from the effects of SHIN1 as with HCT116 cells, but rather paradoxically potentiated SHIN1 effects. Cytotoxicity was not due to 1C depletion, but instead was due to glycine deficiency being exacerbated by formate excess, which drives SHMT catalysis in the glycine-consuming (glycine → serine) direction. Despite these promising in vitro results, SHIN1 showed a disappointing lack of in vivo antitumor efficacy (36), likely due to its poor pharmacokinetics and/or metabolic instability.

To improve on these shortcomings of SHIN1, Rabinowitz and colleagues synthesized a next-generation pyrazolopyran compound, SHIN2 (Fig. 3D; ref. 114). Like SHIN1, SHIN2 induced metabolic derangements consistent with inhibition of SHMT1 and SHMT2. SHIN2 showed potent in vivo inhibition of NOTCH1-induced T-cell acute lymphoblastic leukemia (T-ALL) xenografts in a mouse model at comparatively high doses (200 mg/kg twice a day, 11 days), with efficacy comparable with that of the standard-of-care treatment methotrexate. Moreover, SHIN2 demonstrated efficacy in a methotrexate-resistant PDX T-ALL model. Combination treatment with SHIN2 and methotrexate in the PDX T-ALL model showed a synergistic response, possibly because of methotrexate-induced depletion of cellular tetrahydrofolates, resulting in decreased competition for SHIN2 binding and greater inhibition of SHMT1 and SHMT2.

Discovery of Multi-targeted Inhibitors of SHMT2 and Cytosolic 1C Metabolism at SHMT1 and de novo Purine Biosynthesis

As mitochondrial 1C metabolism from SHMT2 is the major source of 1C units for de novo purine biosynthesis in the cytosol, molecules targeting SHMT2, along with de novo purine biosynthesis at GARFTase and/or AICARFTase, should afford especially potent antitumor agents (35). Primary inhibition of mitochondrial 1C metabolism at SHMT2 would deplete cytosolic formate (e.g., 10-CHO-THF) pools required for nucleotide biosynthesis, potentiating drug efficacy by reducing competition for inhibitor binding at these cytosolic enzyme targets. Moreover, concurrent inhibition of SHMT1 would augment inhibition at SHMT2 by preventing metabolic compensation involving reversal (serine → glycine) of the SHMT1 reaction, analogous to SHIN1 and SHIN2 (36, 114).

To achieve this, Matherly, Gangjee, Dann, and colleagues combined structural features from 5-substituted pyrrolo[2,3-d]pyrimidine inhibitors of de novo purine biosynthesis (115) with those from 5-formyl tetrahydrofolate (a SHMT inhibitor; ref. 116) and 5,10-CH2-THF (SHMT2 product), to generate novel 5-substituted pyrrolo[3,2-d]pyrimidine benzoyl and thienoyl analogs (35). The lead compounds of this series, AGF291, AGF320, and AGF347 (Fig. 4), demonstrated broad range in vitro efficacy toward human tumor cell lines expressing PCFT, including non–small cell lung cancer (H460), colon cancer (HCT116), and pancreatic adenocarcinoma (MIA PaCa2, AsPC1, BxPC3, CFPAC, and HPAC; refs. 27, 35) cells. SHMT2 inhibition was confirmed by targeted metabolomics and flux analysis with [2,3,3-2H]serine, accompanied by direct inhibition of GARFTase and AICARFTase in de novo purine biosynthesis and reduced purine nucleotide pools (35). In vivo antitumor efficacy with curative potential was confirmed with AGF347 in early- and late-stage MIA PaCa2 pancreatic adenocarcinoma xenografts in SCID mice at modest dosing (120 mg/kg total, every 2 days × 8; ref. 35). Toxicity was modest and consisted of limited weight loss that was completely reversible upon completion of therapy.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Multi-targeted inhibitors of SHMT2 and cytosolic 1C metabolism. Structures are shown for 5-subsituted pyrrolo[3,2-d]pyrimidine compounds AGF291, AGF320, and AGF347 (35).

A follow-up study demonstrated that AGF347 accumulated in both the cytosol and mitochondria nearly exclusively (>98%) as polyglutamate conjugates (27). In mitochondria, AGF347 accumulation was mediated, at least in part, by MFT, albeit seemingly less than for folates (27). Treatment of HCT116 cells with AGF347 under hypoxic (0.5% O2) conditions resulted in elevated reactive oxygen species (ROS), accompanied by decreased reduced and total GSH, analogous to HCT116 SHMT2-knockout cells (27). The extent of ROS induction with AGF347 varied with different tumor cell lines (27) However, unlike knockout of SHMT2, treatment of HCT116 cells with AGF347 did not suppress mitochondrial respiration (27), likely due to incomplete inhibition of this mitochondrial target (71).

Conclusions and Future Outlook

In spite of recent advances in targeted therapies for cancer, the classic antifolates, typified by methotrexate and pemetrexed, remain vital components of the therapeutic armamentarium (2). These agents have found important clinical applications for cancer in the United States and abroad. Most recently, PCFT-targeted pyrrolo[2,3-d]pyrimidine antifolate inhibitors were described, with tumor targeting based on their selective membrane transport by PCFT under acidic conditions of the tumor microenvironment (20, 23). Notably, all these agents inhibit 1C metabolism at cytosolic enzymes involved in nucleotide biosynthesis (2, 20, 23).

It is now recognized that 1C metabolism involves compartmentalization of folate cofactors and 1C pathways between the cytosol and mitochondria (4, 7, 8, 28), which extends to the nucleus (29). Even within a particular cellular compartment, regulatory networks and protein associations (e.g., purinosome; ref. 39) can occur, designed to ensure an efficient flow of 1C units for biosynthesis of nucleotides and key amino acids, and/or for methylation of critical genes and/or proteins. It is interesting that enzymes previously considered to localize exclusively in the cytosol are now recognized to be expressed as distinct, but functionally homologous, forms in the mitochondria and nucleus, including SHMT1, SHMT2, and SHMT2α, and MTHFD1, MTHFD1L, and MTHFD2 (4). In some cases, these enzymes appear to perform noncanonical functions in the nucleus or mitochondria (117), although this is controversial. Even within mitochondria, functional redundancies exist between normal tissues (MTHFD2L) and tumors (MTFHD2; refs. 78, 79).

It is of further interest that the mitochondrial 1C enzymes, MTHFD2 and SHMT2, are among the most differentially expressed metabolic enzymes between tumors and normal tissues (59). Serine catabolism in mitochondria ensures that the unique metabolic requirements of hypoxic tumors are met for 1C units, glycine, reducing equivalents, and ATP (4–6, 8), while also ensuring that proteins required for mitochondrial respiration are efficiently translated (70, 71). Although the evolutionary rationale for compartmentalization of 1C metabolism continues to emerge, studies suggest its importance for preserving labile tetrahydrofolates from oxidation (86). Furthermore, compartmentalization of 1C metabolism between cytosol and mitochondrial ensures a directional flux of 1C units, in relation to the high NAD(P)+/NAD(P)H ratios in mitochondria that favor serine oxidation to formate. In the cytosol, low NADP+/NADPH ratios favor synthesis of 10-CHO-THF from formate and tetrahydrofolate (via MTHFD1), and synthesis of serine from glycine and 5,10-CH2-THF (via SHMT1; refs. 28, 86).

Thus, MTHFD2 and SHMT2 are important biomarkers for cancer, the levels of which correlate with tumor aggressiveness and disease progression (9–12, 59, 64–67). Although these enzymes limit 1C units and glycine for cellular biosynthesis in the cytosol, for HCT116 colon cancer cells, SHMT2 knockout results in GSH depletion as the most significant metabolic change, because supplementation with GSH or N-acetylcysteine completely rescues cells from cytotoxicity (45). This suggests that antioxidant synthesis, rather than synthesis of proteins or purine nucleotides, is the major driver of demand for 1C metabolism in mitochondria, at least in HCT116 cells. Indeed, as serum glycine can be abundant, therapeutic efforts to target SHMT2 (or MTHFD2) seem ideally suited for intrinsically glycine-deficient tumors (e.g., diffuse large B-cell lymphoma; ref. 36).

Promising lead inhibitors have been described for SHMT2 (SHIN1, SHIN2, and AGF347; refs. 35, 36, 114) or MTHDF2 (DS18561882; ref. 105). As compensatory metabolic changes in cytosolic fluxes (e.g., SHMT1 reversal) accompany loss of SHMT2 or MTHFD2 and result in viable and tumorigenic cells (35, 45), it will be important to combine targeting mitochondrial 1C metabolism by small molecules with inhibition of other targets (e.g., SHMT1), as seen with SHIN1/SHIN2 (36, 114) and AGF347 (35). For AGF347, in addition to SHMT1, additional direct inhibition of de novo purine biosynthesis at GARFTase and AICARFTase offers targets for which inhibition is independent of wild-type/mutant p53 status (118) and results in suppression of mTOR signaling (119). Selectivity for de novo purine biosynthesis in tumors is further augmented by loss of methylthioadenosine phosphorylase (MTAP) in purine salvage (120). While the mechanisms of cellular uptake of SHIN1/SHIN2 and DS18461882 have not been established, AGF347 is transported into cells by both RFC and PCFT (27). If second-generation analogs of this series with preferential uptake via PCFT were identified, these would afford even greater tumor selectivity (23).

As cancer cells depend on serine biosynthesis from glycolysis in the cytosol, and high serine concentrations were reported in the tumor microenvironment (121), it might be possible to combine inhibitors of SHMT2 or MTHFD2 with inhibitors of upstream targets including DHFR (114), PDGH (122), NRF2 (66), or ATF4 (123). Another possibility is to combine SHMT2 or MTHFD2 inhibitors with approaches for targeting MYC (bromodomain and extra-terminal motif inhibitors; ref. 124), as MYC regulates both SHMT2 and MTHFD2 (6, 62, 81).

In conclusion, the pervasive importance of mitochondrial 1C metabolism to the malignant phenotype demonstrates the immense value of the therapeutic targeting of this critical pathway at SHMT2 and/or MTHFD2, along with other enzymes. By any measure, these new agents afford a valuable and exciting platform for future anticancer drug development.

Disclosure of Potential Conflicts of Interest

L.H. Matherly and A. Gangjee report collaboration with Flag Therapeutics, Inc., an early-stage oncology company focused on the development of novel therapies. No potential conflicts of interest were disclosed by the other authors.

Acknowledgments

This work was supported, in part, by grants R01 CA53535 (to L.H. Matherly and Z. Hou), R01 CA152316 (to L.H. Matherly and A. Gangjee), and R01 CA166711 (to A. Gangjee and L.H. Matherly) from the NIH, a Strategic Initiative Grant from the Barbara Ann Karmanos Cancer Institute (to Z. Hou and L.H. Matherly), the Eunice and Milton Ring Endowed Chair for Cancer Research (to L.H. Matherly), and the Duquesne University Adrian Van Kaam Chair in Scholarly Excellence (to A. Gangjee). This work was also supported by grants T32 CA009531 (to L.H. Matherly) and F30 CA228221 (to A.S. Dekhne).

Footnotes

  • Mol Cancer Ther 2020;19:2245–55

  • Received May 18, 2020.
  • Revision received July 6, 2020.
  • Accepted August 25, 2020.
  • Published first September 2, 2020.
  • ©2020 American Association for Cancer Research.

References

  1. 1.↵
    1. Hanahan D,
    2. Weinberg RA
    . Hallmarks of cancer: the next generation. Cell 2011;144:646–74.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Visentin M,
    2. Zhao R,
    3. Goldman ID
    . The antifolates. Hematol Oncol Clin North Am 2012;26:629–48.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Grem JL
    . 5-fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 2000;18:299–313.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Ducker GS,
    2. Rabinowitz JD
    . One-carbon metabolism in health and disease. Cell Metab 2017;25:27–42.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Locasale JW
    . Serine, glycine and the one-carbon cycle: cancer metabolism in full circle. Nat Rev Cancer 2013;13:572–83.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Ye J,
    2. Fan J,
    3. Venneti S,
    4. Wan YW,
    5. Pawel BR,
    6. Zhang J,
    7. et al.
    Serine catabolism regulates mitochondrial redox control during hypoxia. Cancer Discov 2014;4:1406–17.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Yang M,
    2. Vousden KH
    . Serine and one-carbon metabolism in cancer. Nat Rev Cancer 2016;16:650–62.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Newman AC,
    2. Maddocks ODK
    . One-carbon metabolism in cancer. Br J Cancer 2017;116:1499–504.
    OpenUrl
  9. 9.↵
    1. Liu Y,
    2. Yin C,
    3. Deng MM,
    4. Wang Q,
    5. He XQ,
    6. Li MT,
    7. et al.
    High expression of SHMT2 is correlated with tumor progression and predicts poor prognosis in gastrointestinal tumors. Eur Rev Med Pharmacol Sci 2019;23:9379–92.
    OpenUrl
  10. 10.↵
    1. Ning S,
    2. Ma S,
    3. Saleh AQ,
    4. Guo L,
    5. Zhao Z,
    6. Chen Y
    . SHMT2 overexpression predicts poor prognosis in intrahepatic cholangiocarcinoma. Gastroenterol Res Pract 2018;2018:4369253.
    OpenUrlCrossRef
  11. 11.↵
    1. Noguchi K,
    2. Konno M,
    3. Koseki J,
    4. Nishida N,
    5. Kawamoto K,
    6. Yamada D,
    7. et al.
    The mitochondrial one-carbon metabolic pathway is associated with patient survival in pancreatic cancer. Oncol Lett 2018;16:1827–34.
    OpenUrl
  12. 12.↵
    1. Yin K
    . Positive correlation between expression level of mitochondrial serine hydroxymethyltransferase and breast cancer grade. Onco Targets Ther 2015;8:1069–74.
    OpenUrl
  13. 13.↵
    1. Liu F,
    2. Liu Y,
    3. He C,
    4. Tao L,
    5. He X,
    6. Song H,
    7. et al.
    Increased MTHFD2 expression is associated with poor prognosis in breast cancer. Tumour Biol 2014;35:8685–90.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Kim D,
    2. Fiske BP,
    3. Birsoy K,
    4. Freinkman E,
    5. Kami K,
    6. Possemato R,
    7. et al.
    SHMT2 drives glioma cell survival in the tumor microenvironment but imposes a dependence on glycine clearance. Nature 2015;520:363–7.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Stokstad ELR
    , editor. Historical perspective on key advances in the biochemistry and physiology of folates. New York, NY: Wiley-Liss; 1990.
  16. 16.↵
    1. Appling DR
    . Compartmentation of folate-mediated one-carbon metabolism in eukaryotes. FASEB J 1991;5:2645–51.
    OpenUrlPubMed
  17. 17.↵
    1. Matherly LH,
    2. Hou Z,
    3. Deng Y
    . Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev 2007;26:111–28.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Matherly LH,
    2. Wilson MR,
    3. Hou Z
    . The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1: biology and role in antifolate chemotherapy of cancer. Drug Metab Dispos 2014;42:632–49.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Zhao R,
    2. Diop-Bove N,
    3. Visentin M,
    4. Goldman ID
    . Mechanisms of membrane transport of folates into cells and across epithelia. Annu Rev Nutr 2011;31:177–201.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Desmoulin SK,
    2. Hou Z,
    3. Gangjee A,
    4. Matherly LH
    . The human proton-coupled folate transporter: biology and therapeutic applications to cancer. Cancer Biol Ther 2012;13:1355–73.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Qiu A,
    2. Min SH,
    3. Jansen M,
    4. Malhotra U,
    5. Tsai E,
    6. Cabelof DC,
    7. et al.
    Rodent intestinal folate transporters (SLC46A1): secondary structure, functional properties, and response to dietary folate restriction. Am J Physiol Cell Physiol 2007;293:C1669–78.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Zhao R,
    2. Visentin M,
    3. Suadicani SO,
    4. Goldman ID
    . Inhibition of the proton-coupled folate transporter (PCFT-SLC46A1) by bicarbonate and other anions. Mol Pharmacol 2013;84:95–103.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Matherly LH,
    2. Hou Z,
    3. Gangjee A
    . The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer. Cancer Chemother Pharmacol 2018;81:1–15.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Wilson MR,
    2. Hou Z,
    3. Yang S,
    4. Polin L,
    5. Kushner J,
    6. White K,
    7. et al.
    Targeting nonsquamous nonsmall cell lung cancer via the proton-coupled folate transporter with 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolates. Mol Pharmacol 2016;89:425–34.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Giovannetti E,
    2. Zucali PA,
    3. Assaraf YG,
    4. Funel N,
    5. Gemelli M,
    6. Stark M,
    7. et al.
    Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools. Ann Oncol 2017;28:2725–32.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Hou Z,
    2. Gattoc L,
    3. O'Connor C,
    4. Yang S,
    5. Wallace-Povirk A,
    6. George C,
    7. et al.
    Dual targeting of epithelial ovarian cancer via folate receptor alpha and the proton-coupled folate transporter with 6-substituted pyrrolo[2,3-d]pyrimidine antifolates. Mol Cancer Ther 2017;16:819–30.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Dekhne AS,
    2. Ning C,
    3. Nayeen MJ,
    4. Shah K,
    5. Kalpage H,
    6. Frühauf J,
    7. et al.
    Cellular pharmacodynamics of a novel pyrrolo[3,2-d]pyrimidine inhibitor targeting mitochondrial and cytosolic one-carbon metabolism. Mol Pharmacol 2020;97:9–22.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Tibbetts AS,
    2. Appling DR
    . Compartmentalization of Mammalian folate-mediated one-carbon metabolism. Ann Rev Nutr 2010;30:57–81.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Field MS,
    2. Kamynina E,
    3. Chon J,
    4. Stover PJ
    . Nuclear folate metabolism. Ann Rev Nutr 2018;38:219–43.
    OpenUrl
  30. 30.↵
    1. Lawrence SA,
    2. Hackett JC,
    3. Moran RG
    . Tetrahydrofolate recognition by the mitochondrial folate transporter. J Biol Chem 2011;286:31480–9.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. McCarthy EA,
    2. Titus SA,
    3. Taylor SM,
    4. Jackson-Cook C,
    5. Moran RG
    . A mutation inactivating the mitochondrial inner membrane folate transporter creates a glycine requirement for survival of Chinese hamster cells. J Biol Chem 2004;279:33829–36.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Kuan J,
    2. Saier MH
    . The mitochondrial carrier family of transport proteins: structural, functional, and evolutionary relationships. Crit Rev Biochem Mol Biol 1993;28:209–33.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Lawrence SA,
    2. Titus SA,
    3. Ferguson J,
    4. Heineman AL,
    5. Taylor SM,
    6. Moran RG
    . Mammalian mitochondrial and cytosolic folylpolyglutamate synthetase maintain the subcellular compartmentalization of folates. J Biol Chem 2014;289:29386–96.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Shane B
    . Folylpolyglutamate synthesis and role in the regulation of one-carbon metabolism. Vitam Horm 1989;45:263–335.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Dekhne AS,
    2. Shah K,
    3. Ducker GS,
    4. Katinas JM,
    5. Wong-Roushar J,
    6. Nayeen MJ,
    7. et al.
    Novel pyrrolo[3,2-d]pyrimidine compounds target mitochondrial and cytosolic one-carbon metabolism with broad-spectrum antitumor efficacy. Mol Cancer Ther 2019;10:1787–99.
    OpenUrl
  36. 36.↵
    1. Ducker GS,
    2. Ghergurovich JM,
    3. Mainolfi N,
    4. Suri V,
    5. Jeong SK,
    6. Hsin-Jung Li S,
    7. et al.
    Human SHMT inhibitors reveal defective glycine import as a targetable metabolic vulnerability of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A 2017;114:11404–9.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    1. Tang X,
    2. Fu X,
    3. Liu Y,
    4. Yu D,
    5. Cai SJ,
    6. Yang C
    . Blockade of glutathione metabolism in IDH1-mutated glioma. Mol Cancer Ther 2020;19:221–30.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Hum DW,
    2. Bell AW,
    3. Rozen R,
    4. MacKenzie RE
    . Primary structure of a human trifunctional enzyme. Isolation of a cDNA encoding methylenetetrahydrofolate dehydrogenase-methenyltetrahydrofolate cyclohydrolase-formyltetrahydrofolate synthetase. J Biol Chem 1988;263:15946–50.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Pedley AM,
    2. Benkovic SJ
    . A new view into the regulation of purine metabolism: the purinosome. Trends Biochem Sci 2017;42:141–54.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Anderson DD,
    2. Quintero CM,
    3. Stover PJ
    . Identification of a de novo thymidylate biosynthesis pathway in mammalian mitochondria. Proc Natl Acad Sci U S A 2011;108:15163–8.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    1. Wong NA,
    2. Brett L,
    3. Stewart M,
    4. Leitch A,
    5. Longley DB,
    6. Dunlop MG,
    7. et al.
    Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma. Br J Cancer 2001;85:1937–43.
    OpenUrlCrossRefPubMed
  42. 42.↵
    1. Matthews RG
    . Methylenetetrahydrofolate reductase from pig liver. Methods Enzymol 1986;122:372–81.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Chen LH,
    2. Liu ML,
    3. Hwang HY,
    4. Chen LS,
    5. Korenberg J,
    6. Shane B
    . Human methionine synthase. cDNA cloning, gene localization, and expression. J Biol Chem 1997;272:3628–34.
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    1. Lu SC
    . S-adenosylmethionine. Int J Biochem Cell Biol 2000;32:391–5.
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. Ducker GS,
    2. Chen L,
    3. Morscher RJ,
    4. Ghergurovich JM,
    5. Esposito M,
    6. Teng X,
    7. et al.
    Reversal of cytosolic one-carbon flux compensates for loss of the mitochondrial folate pathway. Cell Metab 2016;23:1140–53.
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Guiducci G,
    2. Paone A,
    3. Tramonti A,
    4. Giardina G,
    5. Rinaldo S,
    6. Bouzidi A,
    7. et al.
    The moonlighting RNA-binding activity of cytosolic serine hydroxymethyltransferase contributes to control compartmentalization of serine metabolism. Nucleic Acids Res 2019;47:4240–54.
    OpenUrl
  47. 47.↵
    1. Anderson DD,
    2. Stover PJ
    . SHMT1 and SHMT2 are functionally redundant in nuclear de novo thymidylate biosynthesis. PLoS One 2009;4:e5839.
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. Meiser J,
    2. Vazquez A
    . Give it or take it: the flux of one-carbon in cancer cells. FEBS J 2016;283:3695–704.
    OpenUrl
  49. 49.↵
    1. Murthy S,
    2. Reddy GP-V
    . Replitase: complete machinery for DNA synthesis. J Cell Phys 2006;209:711–7.
    OpenUrlCrossRefPubMed
  50. 50.↵
    1. Gustafsson Sheppard N,
    2. Jarl L,
    3. Mahadessian D,
    4. Strittmatter L,
    5. Schmidt A,
    6. Madhusudan N,
    7. et al.
    The folate-coupled enzyme MTHFD2 is a nuclear protein and promotes cell proliferation. Sci Rep 2015;5:15029.
    OpenUrl
  51. 51.↵
    1. Koufaris C,
    2. Nilsson R
    . Protein interaction and functional data indicate MTHFD2 involvement in RNA processing and translation. Cancer Metab 2018;6:12.
    OpenUrlCrossRefPubMed
  52. 52.↵
    1. Green NH,
    2. Galvan DL,
    3. Badal SS,
    4. Chang BH,
    5. LeBleu VS,
    6. Long J,
    7. et al.
    MTHFD2 links RNA methylation to metabolic reprogramming in renal cell carcinoma. Oncogene 2019;38:6211–25.
    OpenUrl
  53. 53.↵
    1. Possemato R,
    2. Marks KM,
    3. Shaul YD,
    4. Pacold ME,
    5. Kim D,
    6. Birsoy K,
    7. et al.
    Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 2011;476:346–50.
    OpenUrlCrossRefPubMed
  54. 54.↵
    1. Amelio I,
    2. Cutruzzolá F,
    3. Antonov A,
    4. Agostini M,
    5. Melino G
    . Serine and glycine metabolism in cancer. Trends Biochem Sci 2014;39:191–8.
    OpenUrlCrossRefPubMed
  55. 55.↵
    1. Locasale JW,
    2. Grassian AR,
    3. Melman T,
    4. Lyssiotis CA,
    5. Mattaini KR,
    6. Bass AJ,
    7. et al.
    Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 2011;43:869–74.
    OpenUrlCrossRefPubMed
  56. 56.↵
    1. Sugimoto E,
    2. Pizer LI
    . The mechanism of end product inhibition of serine biosynthesis. I. Purification and kinetics of phosphoglycerate dehydrogenase. J Biol Chem 1968;243:2081–9.
    OpenUrlAbstract/FREE Full Text
  57. 57.↵
    1. Chaneton B,
    2. Hillmann P,
    3. Zheng L,
    4. Martin ACL,
    5. Maddocks ODK,
    6. Chokkathukalam A,
    7. et al.
    Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature 2012;491:458–62.
    OpenUrlCrossRefPubMed
  58. 58.↵
    1. Kory N,
    2. Wyant GA,
    3. Prakash G,
    4. Uit de Bos J,
    5. Bottanelli F,
    6. Pacold ME,
    7. et al.
    SFXN1 is a mitochondrial serine transporter required for one-carbon metabolism. Science 2018;362:eaat9528.
    OpenUrlAbstract/FREE Full Text
  59. 59.↵
    1. Nilsson R,
    2. Jain M,
    3. Madhusudhan N,
    4. Sheppard NG,
    5. Strittmatter L,
    6. Kampf C,
    7. et al.
    Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer. Nat Commun 2014;5:4128.
    OpenUrl
  60. 60.↵
    1. Jain M,
    2. Nilsson R,
    3. Sharma S,
    4. Madhusudhan N,
    5. Kitami T,
    6. Souza AL,
    7. et al.
    Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 2012;336:1040–4.
    OpenUrlAbstract/FREE Full Text
  61. 61.↵
    1. Badar T,
    2. Patel KP,
    3. Thompson PA,
    4. DiNardo C,
    5. Takahashi K,
    6. Cabrero M,
    7. et al.
    Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leuk Res 2015;39:1367–74.
    OpenUrl
  62. 62.↵
    1. Nikiforov MA,
    2. Chandriani S,
    3. O'Connell B,
    4. Petrenko O,
    5. Kotenko I,
    6. Beavis A,
    7. et al.
    A functional screen for Myc-responsive genes reveals serine hydroxymethyltransferase, a major source of the one-carbon unit for cell metabolism. Mol Cell Biol 2002;22:5793–800.
    OpenUrlAbstract/FREE Full Text
  63. 63.↵
    1. Shin M,
    2. Momb J,
    3. Appling DR
    . Human mitochondrial MTHFD2 is a dual redox cofactor-specific methylenetetrahydrofolate dehydrogenase/methenyltetrahydrofolate cyclohydrolase. Cancer Metab 2017;5:11.
    OpenUrlCrossRef
  64. 64.↵
    1. Li AM,
    2. Ducker GS,
    3. Li Y,
    4. Seoane JA,
    5. Xiao Y,
    6. Melemenidis S,
    7. et al.
    Metabolic profiling reveals a dependency of human metastatic breast cancer on mitochondrial serine and one-carbon unit metabolism. Mol Cancer Res 2020;18:599–611.
    OpenUrlAbstract/FREE Full Text
  65. 65.↵
    1. Zhang L,
    2. Chen Z,
    3. Xue D,
    4. Zhang Q,
    5. Liu X,
    6. Luh F,
    7. et al.
    Prognostic and therapeutic value of mitochondrial serine hydroxyl-methyltransferase 2 as a breast cancer biomarker. Oncol Rep 2016;36:2489–500.
    OpenUrl
  66. 66.↵
    1. DeNicola GM,
    2. Chen PH,
    3. Mullarky E,
    4. Sudderth JA,
    5. Hu Z,
    6. Wu D,
    7. et al.
    NRF2 regulates serine biosynthesis in non-small cell lung cancer. Nat Genet 2015;47:1475–81.
    OpenUrlCrossRefPubMed
  67. 67.↵
    1. Wu M,
    2. Wanggou S,
    3. Li X,
    4. Liu Q,
    5. Xie Y
    . Overexpression of mitochondrial serine hydroxyl-methyltransferase 2 is associated with poor prognosis and promotes cell proliferation and invasion in gliomas. Onco Targets Ther 2017;10:3781–8.
    OpenUrl
  68. 68.↵
    1. Fan J,
    2. Ye J,
    3. Kamphorst JJ,
    4. Shlomi T,
    5. Thompson CB,
    6. Rabinowitz JD
    . Quantitative flux analysis reveals folate-dependent NADPH production. Nature 2014;510:298–302.
    OpenUrlCrossRefPubMed
  69. 69.↵
    1. di Salvo ML,
    2. Contestabile R,
    3. Paiardini A,
    4. Maras B
    . Glycine consumption and mitochondrial serine hydroxymethyltransferase in cancer cells: the heme connection. Med Hypotheses 2013;80:633–6.
    OpenUrlCrossRefPubMed
  70. 70.↵
    1. Morscher RJ,
    2. Ducker GS,
    3. Li SH,
    4. Mayer JA,
    5. Gitai Z,
    6. Sperl W,
    7. et al.
    Mitochondrial translation requires folate-dependent tRNA methylation. Nature 2018;554:128–32.
    OpenUrlCrossRefPubMed
  71. 71.↵
    1. Minton DR,
    2. Nam M,
    3. McLaughlin DJ,
    4. Shin J,
    5. Bayraktar EC,
    6. Alvarez SW,
    7. et al.
    Serine catabolism by SHMT2 is required for proper mitochondrial translation initiation and maintenance of formylmethionyl-tRNAs. Mol Cell 2018;69:610–21.
    OpenUrlCrossRefPubMed
  72. 72.↵
    1. Witt O,
    2. Deubzer HE,
    3. Milde T,
    4. Oehme I
    . HDAC family: what are the cancer relevant targets? Cancer Lett 2009;277:8–21.
    OpenUrlCrossRefPubMed
  73. 73.↵
    1. Yang X,
    2. Wang Z,
    3. Li X,
    4. Liu B,
    5. Liu M,
    6. Liu L,
    7. et al.
    SHMT2 desuccinylation by SIRT5 drives cancer cell proliferation. Cancer Res 2018;78:372–86.
    OpenUrlAbstract/FREE Full Text
  74. 74.↵
    1. Giardina G,
    2. Brunotti P,
    3. Fiascarelli A,
    4. Cicalini A,
    5. Costa MGS,
    6. Buckle AM,
    7. et al.
    How pyridoxal 5′-phosphate differentially regulates human cytosolic and mitochondrial serine hydroxymethyltransferase oligomeric state. FEBS J 2015;282:1225–41.
    OpenUrl
  75. 75.↵
    1. Walden M,
    2. Tian L,
    3. Ross RL,
    4. Sykora UM,
    5. Byrne DP,
    6. Hesketh EL,
    7. et al.
    Metabolic control of BRISC-SHMT2 assembly regulates immune signalling. Nature 2019;570:194–9.
    OpenUrlCrossRef
  76. 76.↵
    1. Cao J,
    2. Sun L,
    3. Aramsangtienchai P,
    4. Spiegelman NA,
    5. Zhang X,
    6. Huang W,
    7. et al.
    HDAC11 regulates type I interferon signaling through defatty-acylation of SHMT2. Proc Natl Acad Sci U S A 2019;116:5487–92.
    OpenUrlAbstract/FREE Full Text
  77. 77.↵
    1. Deubzer HE,
    2. Schier MC,
    3. Oehme I,
    4. Lodrini M,
    5. Haendler B,
    6. Sommer A,
    7. et al.
    HDAC11 is a novel drug target in carcinomas. Int J Cancer 2013;132:2200–8.
    OpenUrlCrossRefPubMed
  78. 78.↵
    1. Christensen KE,
    2. Mackenzie RE
    . Mitochondrial methylenetetrahydrofolate dehydrogenase, methenyltetrahydrofolate cyclohydrolase, and formyltetrahydrofolate synthetases. Vitam Horm 2008;79:393–410.
    OpenUrlCrossRefPubMed
  79. 79.↵
    1. Shin M,
    2. Bryant JD,
    3. Momb J,
    4. Appling DR
    . Mitochondrial MTHFD2L is a dual redox cofactor-specific methylenetetrahydrofolate dehydrogenase/methenyltetrahydrofolate cyclohydrolase expressed in both adult and embryonic tissues. J Biol Chem 2014;289:15507–17.
    OpenUrlAbstract/FREE Full Text
  80. 80.↵
    1. Nilsson R,
    2. Nicolaidou V,
    3. Koufaris C
    . Mitochondrial MTHFD isozymes display distinct expression, regulation, and association with cancer. Gene 2019;716:144032.
    OpenUrl
  81. 81.↵
    1. Pikman Y,
    2. Puissant A,
    3. Alexe G,
    4. Furman A,
    5. Chen LM,
    6. Frumm SM,
    7. et al.
    Targeting MTHFD2 in acute myeloid leukemia. J Exp Med 2016;213:1285–306.
    OpenUrlAbstract/FREE Full Text
  82. 82.↵
    1. Ben-Sahra I,
    2. Hoxhaj G,
    3. Ricoult SJH,
    4. Asara JM,
    5. Manning BD
    . mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle. Science 2016;351:728–33.
    OpenUrlAbstract/FREE Full Text
  83. 83.↵
    1. Nishimura T,
    2. Nakata A,
    3. Chen X,
    4. Nishi K,
    5. Meguro-Horike M,
    6. Sasaki S,
    7. et al.
    Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2. Oncogene 2019;38:2464–81.
    OpenUrlCrossRef
  84. 84.↵
    1. Meiser J,
    2. Tumanov S,
    3. Maddocks O,
    4. Labuschagne CF,
    5. Athineos D,
    6. Van Den Broek N,
    7. et al.
    Serine one-carbon catabolism with formate overflow. Sci Adv 2016;2:e1601273.
    OpenUrlFREE Full Text
  85. 85.↵
    1. Meiser J,
    2. Schuster A,
    3. Pietzke M,
    4. Vande Voorde J,
    5. Athineos D,
    6. Oizel K,
    7. et al.
    Increased formate overflow is a hallmark of oxidative cancer. Nat Commun 2018;9:368.
    OpenUrlCrossRefPubMed
  86. 86.↵
    1. Zheng Y,
    2. Lin TY,
    3. Lee G,
    4. Paddock MN,
    5. Momb J,
    6. Cheng Z,
    7. et al.
    Mitochondrial one-carbon pathway supports cytosolic folate integrity in cancer cells. Cell 2018;175:1546–60.
    OpenUrlCrossRef
  87. 87.↵
    1. Kikuchi G,
    2. Motokawa Y,
    3. Yoshida T,
    4. Hiraga K
    . Glycine cleavage system: reaction mechanism, physiological significance, and hyperglycinemia. Proc Jpn Acad Ser B Phys Biol Sci 2008;84:246–63.
    OpenUrlCrossRefPubMed
  88. 88.↵
    1. Zhang WC,
    2. Shyh-Chang N,
    3. Yang H,
    4. Rai A,
    5. Umashankar S,
    6. Ma S,
    7. et al.
    Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell 2012;148:259–72.
    OpenUrlCrossRefPubMed
  89. 89.↵
    1. Labuschagne CF,
    2. van den Broek NJ,
    3. Mackay GM,
    4. Vousden KH,
    5. Maddocks OD
    . Serine, but not glycine, supports one-carbon metabolism and proliferation of cancer cells. Cell Rep 2014;7:1248–58.
    OpenUrlCrossRefPubMed
  90. 90.↵
    1. Krupenko SA,
    2. Krupenko NI
    . ALDH1L1 and ALDH1L2 folate regulatory enzymes in cancer. Adv Exp Med Biol 2018;1032:127–43.
    OpenUrl
  91. 91.↵
    1. Piskounova E,
    2. Agathocleous M,
    3. Murphy MM,
    4. Hu Z,
    5. Huddlestun SE,
    6. Zhao Z,
    7. et al.
    Oxidative stress inhibits distant metastasis by human melanoma cells. Nature 2015;527:186–91.
    OpenUrlCrossRefPubMed
  92. 92.↵
    1. Wu S,
    2. Lu H,
    3. Bai Y
    . Nrf2 in cancers: a double-edged sword. Cancer Med 2019;8:2252–67.
    OpenUrl
  93. 93.↵
    1. Okazaki K,
    2. Papagiannakopoulos T,
    3. Motohashi H
    . Metabolic features of cancer cells in NRF2 addiction status. Biophys Rev 2020;12:435–41.
    OpenUrl
  94. 94.↵
    1. Yu D,
    2. Liu Y,
    3. Zhou Y,
    4. Ruiz-Rodado V,
    5. Larion M,
    6. Xu G,
    7. et al.
    Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism. Proc Natl Acad Sci U S A 2020;117:9964–72.
    OpenUrlAbstract/FREE Full Text
  95. 95.↵
    1. Mitsuishi Y,
    2. Taguchi K,
    3. Kawatani Y,
    4. Shibata T,
    5. Nukiwa T,
    6. Aburatani H,
    7. et al.
    Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 2012;22:66–79.
    OpenUrlCrossRefPubMed
  96. 96.↵
    1. Maddocks OD,
    2. Berkers CR,
    3. Mason SM,
    4. Zheng L,
    5. Blyth K,
    6. Gottlieb E,
    7. et al.
    Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature 2013;493:542–6.
    OpenUrlCrossRefPubMed
  97. 97.↵
    1. Lehtinen L,
    2. Ketola K,
    3. Makela R,
    4. Mpindi JP,
    5. Viitala M,
    6. Kallioniemi O,
    7. et al.
    High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion. Oncotarget 2013;4:48–63.
    OpenUrlCrossRef
  98. 98.↵
    1. Koufaris C,
    2. Gallage S,
    3. Yang T,
    4. Lau CH,
    5. Valbuena GN,
    6. Keun HC
    . Suppression of MTHFD2 in MCF-7 breast cancer cells increases glycolysis, dependency on exogenous glycine, and sensitivity to folate depletion. J Proteome Res 2016;15:2618–25.
    OpenUrlPubMed
  99. 99.↵
    1. Schmidt A,
    2. Wu H,
    3. MacKenzie RE,
    4. Chen VJ,
    5. Bewly JR,
    6. Ray JE,
    7. et al.
    Structures of three inhibitor complexes provide insight into the reaction mechanism of the human methylenetetrahydrofolate dehydrogenase/cyclohydrolase. Biochem J 2000;39:6325–35.
    OpenUrl
  100. 100.↵
    1. Eadsforth TC,
    2. Gardiner M,
    3. Maluf FV,
    4. McElroy S,
    5. James D,
    6. Frearson J,
    7. et al.
    Assessment of Pseudomonas aeruginosa N5,N10-methylenetetrahydrofolate dehydrogenase-cyclohydrolase as a potential antibacterial drug target. PLoS One 2012;7:e35973.
    OpenUrlPubMed
  101. 101.↵
    1. Fu C,
    2. Sikandar A,
    3. Donner J,
    4. Zaburannyi N,
    5. Herrmann J,
    6. Reck M,
    7. et al.
    The natural product carolacton inhibits folate-dependent C1 metabolism by targeting FolD/MTHFD. Nat Commun 2017;8:1529.
    OpenUrlCrossRef
  102. 102.↵
    1. Gustafsson R,
    2. Jemth A-S,
    3. Gustafsson NMS,
    4. Färnegårdh K,
    5. Loseva O,
    6. Wiita E,
    7. et al.
    Crystal structure of the emerging cancer target MTHFD2 in complex with a substrate-based inhibitor. Cancer Res 2017;77:937–48.
    OpenUrlAbstract/FREE Full Text
  103. 103.↵
    1. Ju HQ,
    2. Lu YX,
    3. Chen DL,
    4. Zuo ZX,
    5. Liu ZX,
    6. Wu QN,
    7. et al.
    Modulation of redox homeostasis by inhibition of MTHFD2 in colorectal cancer: mechanisms and therapeutic implications. J Natl Cancer Inst 2019;111:584–96.
    OpenUrl
  104. 104.↵
    1. Kawai J,
    2. Ota M,
    3. Ohki H,
    4. Toki T,
    5. Suzuki M,
    6. Shimada T,
    7. et al.
    Structure-based design and synthesis of an isozyme-selective MTHFD2 inhibitor with a tricyclic coumarin scaffold. ACS Med Chem Lett 2019;10:893–8.
    OpenUrl
  105. 105.↵
    1. Kawai J,
    2. Toki T,
    3. Ota M,
    4. Inoue H,
    5. Takata Y,
    6. Asahi T,
    7. et al.
    Discovery of a potent, selective, and orally available MTHFD2 inhibitor (DS18561882) with in vivo antitumor activity. J Med Chem 2019;62:10204–20.
    OpenUrl
  106. 106.↵
    1. Paiardini A,
    2. Fiascarelli A,
    3. Rinaldo S,
    4. Daidone F,
    5. Giardina G,
    6. Koes DR,
    7. et al.
    Screening and in vitro testing of antifolate inhibitors of human cytosolic serine hydroxymethyltransferase. ChemMedChem 2015;10:490–7.
    OpenUrlCrossRefPubMed
  107. 107.↵
    1. Daidone F,
    2. Florio R,
    3. Rinaldo S,
    4. Contestabile R,
    5. di Salvo ML,
    6. Cutruzzola F,
    7. et al.
    In silico and in vitro validation of serine hydroxymethyltransferase as a chemotherapeutic target of the antifolate drug pemetrexed. Eur J Med Chem 2011;46:1616–21.
    OpenUrlCrossRefPubMed
  108. 108.↵
    1. Shih C,
    2. Chen VJ,
    3. Gossett LS,
    4. Gates SB,
    5. MacKellar WC,
    6. Habeck LL,
    7. et al.
    LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116–23.
    OpenUrlAbstract/FREE Full Text
  109. 109.↵
    1. Scaletti E,
    2. Jemth AS,
    3. Helleday T,
    4. Stenmark P
    . Structural basis of inhibition of the human serine hydroxymethyltransferase SHMT2 by antifolate drugs. FEBS Lett 2019;593:1863–73.
    OpenUrl
  110. 110.↵
    1. Witschel M,
    2. Stelzer F,
    3. Hutzler J,
    4. Qu T,
    5. Mietzner T,
    6. Kreuz K,
    7. et al.
    , inventors; BASF SE, assignee. Pyrazolopyrans having herbicidal and pharmaceutical properties. European Patent Office EP2858981A1. 2013 May 29.
  111. 111.↵
    1. Witschel MC,
    2. Rottmann M,
    3. Schwab A,
    4. Leartsakulpanich U,
    5. Chitnumsub P,
    6. Seet M,
    7. et al.
    Inhibitors of plasmodial serine hydroxymethyltransferase (SHMT): cocrystal structures of pyrazolopyrans with potent blood- and liver-stage activities. J Med Chem 2015;58:3117–30.
    OpenUrlCrossRefPubMed
  112. 112.↵
    1. Marani M,
    2. Paone A,
    3. Fiascarelli A,
    4. Macone A,
    5. Gargano M,
    6. Rinaldo S,
    7. et al.
    A pyrazolopyran derivative preferentially inhibits the activity of human cytosolic serine hydroxymethyltransferase and induces cell death in lung cancer cells. Oncotarget 2016;7:4570–83.
    OpenUrlCrossRefPubMed
  113. 113.↵
    1. Ma EH,
    2. Bantug G,
    3. Griss T,
    4. Condotta S,
    5. Johnson RM,
    6. Samborska B,
    7. et al.
    Serine is an essential metabolite for effector T cell expansion. Cell Metab 2017;25:345–57.
    OpenUrlCrossRefPubMed
  114. 114.↵
    1. García-Cañaveras JC,
    2. Lancho O,
    3. Ducker GS,
    4. Ghergurovich JM,
    5. Xu X,
    6. da Silva-Diz V,
    7. et al.
    SHMT inhibition is effective and synergizes with methotrexate in T-cell acute lymphoblastic leukemia. Leukemia 2020 May 7 [Epub ahead of print].
  115. 115.↵
    1. Mitchell-Ryan S,
    2. Wang Y,
    3. Raghavan S,
    4. Ravindra MP,
    5. Hales E,
    6. Orr S,
    7. et al.
    Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implications of inhibiting 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase to AMPK activation and anti-tumor activity. J Med Chem 2013;56:10016–32.
    OpenUrlCrossRefPubMed
  116. 116.↵
    1. Chang WN,
    2. Tsai JN,
    3. Chen BH,
    4. Huang HS,
    5. Fu TF
    . Serine hydroxymethyltransferase isoforms are differentially inhibited by leucovorin: characterization and comparison of recombinant zebrafish serine hydroxymethyltransferases. Drug Metab Dispos 2007;35:2127–37.
    OpenUrlAbstract/FREE Full Text
  117. 117.↵
    1. Anderson DD,
    2. Woeller CF,
    3. Chiang EP,
    4. Shane B,
    5. Stover PJ
    . Serine hydroxymethyltransferase anchors de novo thymidylate synthesis pathway to nuclear lamina for DNA synthesis. J Biol Chem 2012;287:7051–62.
    OpenUrlAbstract/FREE Full Text
  118. 118.↵
    1. Bronder JL,
    2. Moran RG
    . Antifolates targeting purine synthesis allow entry of tumor cells into S phase regardless of p53 function. Cancer Res 2002;62:5236–41.
    OpenUrlAbstract/FREE Full Text
  119. 119.↵
    1. Hoxhaj G,
    2. Hughes-Hallett J,
    3. Timson RC,
    4. Ilagan E,
    5. Yuan M,
    6. Asara JM,
    7. et al.
    The mTORC1 signaling network senses changes in cellular purine nucleotide levels. Cell Rep 2017;21:1331–46.
    OpenUrlCrossRef
  120. 120.↵
    1. Bertino JR,
    2. Waud WR,
    3. Parker WB,
    4. Lubin M
    . Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategies. Cancer Biol Ther 2011;11:627–32.
    OpenUrlCrossRefPubMed
  121. 121.↵
    1. Goveia J,
    2. Pircher A,
    3. Conradi LC,
    4. Kalucka J,
    5. Lagani V,
    6. Dewerchin M,
    7. et al.
    Meta-analysis of clinical metabolic profiling studies in cancer: challenges and opportunities. EMBO Mol Med 2016;8:1134–42.
    OpenUrlAbstract/FREE Full Text
  122. 122.↵
    1. Ravez S,
    2. Spillier Q,
    3. Marteau R,
    4. Feron O,
    5. Frederick R
    . Challenges and opportunities in the development of serine synthetic pathway inhibitors for cancer therapy. J Med Chem 2017;60:1227–37.
    OpenUrl
  123. 123.↵
    1. Linares JF,
    2. Cordes T,
    3. Duran A,
    4. Reina-Campos M,
    5. Valencia T,
    6. Ahn CS,
    7. et al.
    ATF4-Induced metabolic reprograming is a synthetic vulnerability of the p62-deficient tumor stroma. Cell Metab 2017;26:817–29.
    OpenUrlCrossRefPubMed
  124. 124.↵
    1. Cochran AG,
    2. Conery AR,
    3. Sims RJ III.
    . Bromodomains: a new target class for drug development. Nat Rev Drug Discov 2019;18:609–28.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
Molecular Cancer Therapeutics: 19 (11)
November 2020
Volume 19, Issue 11
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Therapeutic Targeting of Mitochondrial One-Carbon Metabolism in Cancer
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Therapeutic Targeting of Mitochondrial One-Carbon Metabolism in Cancer
Aamod S. Dekhne, Zhanjun Hou, Aleem Gangjee and Larry H. Matherly
Mol Cancer Ther November 1 2020 (19) (11) 2245-2255; DOI: 10.1158/1535-7163.MCT-20-0423

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Therapeutic Targeting of Mitochondrial One-Carbon Metabolism in Cancer
Aamod S. Dekhne, Zhanjun Hou, Aleem Gangjee and Larry H. Matherly
Mol Cancer Ther November 1 2020 (19) (11) 2245-2255; DOI: 10.1158/1535-7163.MCT-20-0423
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Folate Homeostasis and Compartmentation of Cellular 1C Metabolism
    • Serine Biosynthesis, Mitochondrial 1C Metabolism, and Cancer
    • Discovery of MTHFD2 Inhibitors for Cancer
    • Discovery of SHMT2-targeted Therapeutics for Cancer
    • Discovery of Multi-targeted Inhibitors of SHMT2 and Cytosolic 1C Metabolism at SHMT1 and de novo Purine Biosynthesis
    • Conclusions and Future Outlook
    • Disclosure of Potential Conflicts of Interest
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Targeting STAT3 with PROTACs and Next-Generation ASOs
  • PIM Kinases Promote Resistance to Therapy
  • CAR-T Cell Therapy to Target TNBC
Show more Review
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement